Charles River, Gruenenthal, Nordic Bioscience deal

Argenta Discovery 2009 Ltd. partnered with Gruenenthal and Nordic Bioscience to develop preclinical and clinical assays to optimize the identification of new fibrosis therapies. Argenta will provide preclinical models, primary cell-based assays, in vivo pharmacology and fibrosis research. Nordic Bioscience will bring experience in organ fibrosis and biomarker selection of disease subsegments, and Gruenenthal will provide expertise on drug discovery and development and coordinate activities. Nordic Bioscience deferred questions to Gruenenthal, which declined to disclose details regarding funding and who will own rights to IP or products generated under the deal. ...